European Union - English - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - midazolam - epilepsy - psycholeptics - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.for infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

European Union - English - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressants - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neuraxpharm france - suxamethonium chloride hydrate 50 mg/ml - eq. suxamethonium chloride 45,45 mg/ml - solution for injection - 50 mg/ml - suxamethonium chloride hydrate 50 mg/ml - suxamethonium

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neuraxpharm france - suxamethonium chloride hydrate 50 mg/ml - eq. suxamethonium chloride 45,45 mg/ml - solution for injection - 50 mg/ml - suxamethonium chloride hydrate 100 mg - suxamethonium